490 related articles for article (PubMed ID: 32417270)
1. MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system.
Huelse JM; Fridlyand DM; Earp S; DeRyckere D; Graham DK
Pharmacol Ther; 2020 Sep; 213():107577. PubMed ID: 32417270
[TBL] [Abstract][Full Text] [Related]
2. MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.
McDaniel NK; Cummings CT; Iida M; Hülse J; Pearson HE; Vasileiadi E; Parker RE; Orbuch RA; Ondracek OJ; Welke NB; Kang GH; Davies KD; Wang X; Frye SV; Earp HS; Harari PM; Kimple RJ; DeRyckere D; Graham DK; Wheeler DL
Mol Cancer Ther; 2018 Nov; 17(11):2297-2308. PubMed ID: 30093568
[TBL] [Abstract][Full Text] [Related]
3. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.
Lee-Sherick AB; Jacobsen KM; Henry CJ; Huey MG; Parker RE; Page LS; Hill AA; Wang X; Frye SV; Earp HS; Jordan CT; DeRyckere D; Graham DK
JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385715
[TBL] [Abstract][Full Text] [Related]
4. Effects of MERTK Inhibitors UNC569 and UNC1062 on the Growth of Acute Myeloid Leukaemia Cells.
Koda Y; Itoh M; Tohda S
Anticancer Res; 2018 Jan; 38(1):199-204. PubMed ID: 29277773
[TBL] [Abstract][Full Text] [Related]
5. UNC5293, a potent, orally available and highly MERTK-selective inhibitor.
Zheng H; Zhao J; Li B; Zhang W; Stashko MA; Minson KA; Huey MG; Zhou Y; Earp HS; Kireev D; Graham DK; DeRyckere D; Frye SV; Wang X
Eur J Med Chem; 2021 Aug; 220():113534. PubMed ID: 34038857
[TBL] [Abstract][Full Text] [Related]
6. MERTK as a novel therapeutic target in head and neck cancer.
von Mässenhausen A; Sanders C; Thewes B; Deng M; Queisser A; Vogel W; Kristiansen G; Duensing S; Schröck A; Bootz F; Brossart P; Kirfel J; Heasley L; Brägelmann J; Perner S
Oncotarget; 2016 May; 7(22):32678-94. PubMed ID: 27081701
[TBL] [Abstract][Full Text] [Related]
7. MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme.
Sufit A; Lee-Sherick AB; DeRyckere D; Rupji M; Dwivedi B; Varella-Garcia M; Pierce AM; Kowalski J; Wang X; Frye SV; Earp HS; Keating AK; Graham DK
PLoS One; 2016; 11(10):e0165107. PubMed ID: 27783662
[TBL] [Abstract][Full Text] [Related]
8. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment.
Myers KV; Amend SR; Pienta KJ
Mol Cancer; 2019 May; 18(1):94. PubMed ID: 31088471
[TBL] [Abstract][Full Text] [Related]
9. Small Molecule Inhibition of MERTK Is Efficacious in Non-Small Cell Lung Cancer Models Independent of Driver Oncogene Status.
Cummings CT; Zhang W; Davies KD; Kirkpatrick GD; Zhang D; DeRyckere D; Wang X; Frye SV; Earp HS; Graham DK
Mol Cancer Ther; 2015 Sep; 14(9):2014-22. PubMed ID: 26162689
[TBL] [Abstract][Full Text] [Related]
10. Mertk: An emerging target in cancer biology and immuno-oncology.
Lahey KC; Gadiyar V; Hill A; Desind S; Wang Z; Davra V; Patel R; Zaman A; Calianese D; Birge RB
Int Rev Cell Mol Biol; 2022; 368():35-59. PubMed ID: 35636929
[TBL] [Abstract][Full Text] [Related]
11. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type
Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074
[TBL] [Abstract][Full Text] [Related]
12. TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma.
Holtzhausen A; Harris W; Ubil E; Hunter DM; Zhao J; Zhang Y; Zhang D; Liu Q; Wang X; Graham DK; Frye SV; Earp HS
Cancer Immunol Res; 2019 Oct; 7(10):1672-1686. PubMed ID: 31451482
[TBL] [Abstract][Full Text] [Related]
13. Structure and functions of Mer, an innate immune checkpoint.
Ubil E; Zahid KR
Front Immunol; 2023; 14():1244170. PubMed ID: 37936688
[TBL] [Abstract][Full Text] [Related]
14. TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting.
Peeters MJW; Rahbech A; Thor Straten P
Cancer Immunol Immunother; 2020 Feb; 69(2):237-244. PubMed ID: 31664482
[TBL] [Abstract][Full Text] [Related]
15. Targeting MerTK decreases efferocytosis and increases anti-tumor immune infiltrate in prostate cancer.
Myers Chen KV; de Groot AE; Mendez SA; Mallin MM; Amend SR; Pienta KJ
Med Oncol; 2023 Aug; 40(10):284. PubMed ID: 37644281
[TBL] [Abstract][Full Text] [Related]
16. Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancer.
Kostecki KL; Iida M; Wiley AL; Kimani S; Mehall B; Tetreault K; Alexandridis R; Yu M; Hong S; Salgia R; Bruce JY; Birge RB; Harari PM; Wheeler DL
Head Neck; 2023 May; 45(5):1255-1271. PubMed ID: 36939040
[TBL] [Abstract][Full Text] [Related]
17. Expression of TAM-R in Human Immune Cells and Unique Regulatory Function of MerTK in IL-10 Production by Tolerogenic DC.
Giroud P; Renaudineau S; Gudefin L; Calcei A; Menguy T; Rozan C; Mizrahi J; Caux C; Duong V; Valladeau-Guilemond J
Front Immunol; 2020; 11():564133. PubMed ID: 33101282
[TBL] [Abstract][Full Text] [Related]
18. Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment.
Cruz Cruz J; Allison KC; Page LS; Jenkins AJ; Wang X; Earp HS; Frye SV; Graham DK; Verneris MR; Lee-Sherick AB
Front Immunol; 2023; 14():1146721. PubMed ID: 36960055
[TBL] [Abstract][Full Text] [Related]
19. MerTK activity is not necessary for the proliferation of glioblastoma stem cells.
Hoque M; Wai Wong S; Recasens A; Abbassi R; Nguyen N; Zhang D; Stashko MA; Wang X; Frye S; Day BW; Baell J; Munoz L
Biochem Pharmacol; 2021 Apr; 186():114437. PubMed ID: 33571503
[TBL] [Abstract][Full Text] [Related]
20. MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis.
Cook RS; Jacobsen KM; Wofford AM; DeRyckere D; Stanford J; Prieto AL; Redente E; Sandahl M; Hunter DM; Strunk KE; Graham DK; Earp HS
J Clin Invest; 2013 Aug; 123(8):3231-42. PubMed ID: 23867499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
